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Abstract
Background: As antiretroviral treatment (ART) programmes in resource-limited settings mature, more patients are
experiencing virological failure. Without resistance testing, deciding who should switch to second-line ART can be difficult.
The consequences for second-line outcomes are unclear. In a workplace- and community-based multi-site programme, with
6-monthly virological monitoring, we describe outcomes and predictors of viral suppression on second-line, protease
inhibitor-based ART.
Methods: We used prospectively collected clinic data from patients commencing first-line ART between 1/1/03 and 31/12/
08 to construct a study cohort of patients switched to second-line ART in the presence of a viral load (VL) $400 copies/ml.
Predictors of VL,400 copies/ml within 15 months of switch were assessed using modified Poisson regression to estimate
risk ratios.
Results: 205 workplace patients (91.7% male; median age 43 yrs) and 212 community patients (38.7% male; median age 36
yrs) switched regimens. At switch compared to community patients, workplace patients had a longer duration of viraemia,
higher VL, lower CD4 count, and higher reported non-adherence on first-line ART. Non-adherence was the reported reason
for switching in a higher proportion of workplace patients. Following switch, 48.3% (workplace) and 72.0% (community)
achieved VL,400, with non-adherence (17.9% vs. 1.4%) and virological rebound (35.6% vs. 13.2% with available measures)
reported more commonly in the workplace programme. In adjusted analysis of the workplace programme, lower switch VL
and younger age were associated with VL,400. In the community programme, shorter duration of viraemia, higher CD4
count and transfers into programme on ART were associated with VL,400.
Conclusion: High levels of viral suppression on second-line ART can be, but are not always, achieved in multi-site treatment
programmes with both individual- and programme-level factors influencing outcomes. Strategies to support both
healthcare workers and patients during this switch period need to be evaluated; sub-optimal adherence, particularly in the
workplace programme must be addressed.
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Introduction
As antiretroviral treatment (ART) programmes in resource-
limited settings mature, patients are increasingly experiencing first-
line, non-nucleoside reverse transcriptase inhibitor (NNRTI)-
based, treatment failure necessitating a switch to second-line,
protease inhibitor (PI)-based regimens [1-3]. Current rates of
switching are low [4-5]; by the end of 2010 only 3% of patients in
resource-limited settings (excluding South and Central Americas)
had switched to second-line ART [1]. Low sensitivity of clinico-
immunological definitions of treatment failure are partly respon-
sible for low rates of switching. However programmes, such as
those in South Africa which use virological monitoring, also report
delays [4]. The reasons are likely to include lack of access to
resistance tests to guide decisions, difficulties in excluding non-
adherence as a cause of virological failure, and potentially
concerns regarding cost and limited availability of subsequent
regimens [6-7]. In the absence of resistance tests, deciding who
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has virological failure secondary to resistance is difficult. Studies
from programmes which use routine virological monitoring have
reported that the proportion of patients with no major drug
resistance mutations is 9-60% on first raised viral load (300-1000
copies/ml) [8-12], 6-33% at confirmatory raised viral load (300-
5000 copies/ml) [10,13-15] and 12% at time of switching to
second-line ART [16]; suggesting non-adherence is a major cause
of viraemia at these time-points. Switching patients with no
detectable resistance to second-line ART is arguably unnecessary,
and potentially fails to address the underlying adherence issues.
With limited regimen availability, unnecessary switching may
compromise future treatment options for the individual, and drive
up programme costs. In South Africa second-line ART is
estimated to be 2.4 times more expensive per year in care than
first-line ART [17].
The consequences of remaining on a virologically-failing first-
line regimen include immunological and clinical progression and,
with increasing duration of viraemia, accumulation of resistance
[18-24]. For patients who eventually start second-line ART, the
consequences of a switch strategy based on virological monitoring
without resistance tests, on subsequent outcomes have not been
fully described. Early reports of second-line outcomes appear
promising with 78-87% of patients in care 12 months following
switch, and 77-85% of those achieving viral suppression [25-27].
However, these reports are largely from academic or referral
clinics, and it is unclear if the same outcomes will be seen under
multi-site programmatic conditions.
This study aimed to describe second-line ART outcomes in a
large workplace- and community-based multi-site programme,
where, in line with South African national guidelines, 6-monthly
viral load (VL) monitoring is standard of care. In addition we
assessed whether co-variates available at the time of switch predict
early viral suppression on second-line ART.
Methods
Study Design and Setting
This observational retrospective cohort analysis used prospec-
tively-collected routine clinical data from the ART programmes of
Aurum Institute, South Africa. These programmes, located within
five provinces of South Africa (Gauteng, Free State, Limpopo,
Mpumalanga and North West), comprise a workplace pro-
gramme, with 56 clinics serving employees of predominantly
mining companies; and a community programme, with 81 urban
and peri-urban private general practitioner and non-government
organization clinics serving patients with limited resources [28-29].
In the workplace, patients were eligible for ART (efavirenz
[EFV] or nevirapine [NVP] with zidovudine [AZT], lamivudine
[3TC] until 2008, then tenofovir/emtricitabine thereafter) if
WHO stage IV, CD4#250 cells/mm3, or CD4#350 cells/mm3
plus WHO stage III. In the community programme, criteria for
first-line ART (stavudine [d4T], 3TC, and NVP or EFV) were
WHO stage IV or CD4#200 cells/mm3. Similar criteria for
switching to second-line ART were used in both programmes.
Interventions to improve adherence were instigated following the
first detectable VL, and VL was repeated 3-6 months later. A
switch to second-line ART was recommended in patients with two
raised VLs .1000-5000 in the presence of good adherence.
Second-line ART comprised AZT, didanosine (ddI) and boosted
lopinavir (bLPV); or abacavir (ABC), ddI, bLPV in the community
and workplace programmes, respectively. Patients collected ART
at 1-3 monthly intervals. All HIV-related treatment was free of
charge.
CD4 count and VL were monitored at baseline, 6 weeks and 6
monthly intervals after commencing or switching ART. All
community clinics were doctor-led; however some workplace
clinics were nurse-led with doctors consulted for management of
virological failure. Patients were offered adherence counseling at
each attendance, with intensified counseling for those with
suboptimal adherence.
Study Population
Patients were eligible for inclusion in the study if they (1)
switched from first- to second-line ART between 1/1/2003 and
31/12/2008; (2)$15 years old at switch; and (3) VL.400 copies/
ml at switch (regardless of whether criteria for switching, as per
programme guidelines, were fulfilled). Data up to 31/3/2010 were
included, allowing all patients 15 months potential follow-up.
Data Collection
At each visit, healthcare workers recorded data on symptoms,
self-reported adherence, adverse events, prescriptions and reason
for stopping or changing medication on standardized data
collection forms. Before commencing ART, data were collected
on patient’s self-reported previous exposure to ART. Reasons for
leaving the programme, derived from patient or relative self-
report, and active follow-up of patients missing appointments,
were recorded on deregistration forms. Data capturers entered all
forms into a central database with laboratory data transferred
electronically from the central laboratory. Where civil identifica-
tion numbers were available, deaths were identified through the
National death register; and in the workplace, through employ-
ment records and hospital death registers. Where data were
missing, clinic files were reviewed using a standardised data
collection form. All community sites used a central off-site
pharmacy. These dispensing records were used to confirm
regimens and dates dispensed.
Outcomes
The primary outcome was viral suppression on second-line
ART, which was defined as ever having achieved a VL,400
copies/ml between 2 weeks to 15 months of switching regimens.
Secondary outcomes were defined as (1) alive and in care: no
record of deregistration or loss to follow-up (no clinic contact for
$6 months) by 15 months; (2) change in CD4 count: CD4 at 12
months (+/23 months) minus CD4 count at switch (6 months
before to 2 weeks after switch); (3) reported non-adherence: patient
report of missing any second-line ART based on 7 day recall and/
or healthcare worker recorded treatment interruption for non-
adherence within 15 months of switch.
Risk Factors
Exposures on first-line ART (transfers into programme on
ART, viral suppression, non-adherence), exposures at time of
switch (duration and magnitude of viraemia, CD4 count, reason
for switch, calendar year, number of new NRTIs in switch
regimen) and demographic data (age, sex, programme) were
considered as potential predictors of early virological suppression
on second-line ART. An association between adherence on
second-line ART and viral suppression on second-line ART was
explored, however this variable was not included in our
multivariable analysis as it was considered to lie on the causal
pathway between our exposures of interest and the primary
outcome.
Non-adherence on first-line ART was defined as patient report
of missing any first-line ART based on 7 day recall and/or
Outcomes on Second-Line Antiretroviral Therapy
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healthcare worker recorded treatment interruption for non-
adherence at any time-point on first-line ART. Duration of
viraemia was defined as the time period between the first VL
.400 copies/ml following viral suppression to date of switch,
where all interim VLs were .400 copies/ml. For patients with
more than one episode of viraemia and re-suppression on first-line
ART, only the viraemic period immediately preceding switch was
considered. The variable was categorised as,12 months and $12
months. Not all patients were known to have achieved viral
suppression on first-line ART therefore the following assumptions
were made: (1) ART-naive patients with no evidence of viral
suppression on first-line ART were considered viraemic since
initiating ART; (2) patients who were transferred in with no
subsequent viral suppression on first-line ART were categorised as
viraemic for $12months.
Healthcare workers could document more than one reason for
stopping the NNRTI-regimen. For the purposes of the analysis the
primary reason for switch was defined as treatment failure, non-
adherence or other e.g. toxicity. If, both non-adherence and treatment
failure were documented, the primary reason for switch was
defined as non-adherence; if treatment failure and other reasons
were documented the primary reasons was defined as treatment
failure.
Statistical Analysis
Modified Poisson regression with robust standard variance was
used to estimate the association of exposures with viral suppression
using the risk ratio [30]. This methodology was used, rather than
logistic regression as the probability of the outcome was high and
therefore the rare event assumption (odds and risk of an event are
similar when the outcome is rare) did not hold true. By reporting
risk ratios we avoided the possibility of the odds of an event being
misinterpreted as risk and the strength of association being over-
emphasized. A backwards stepwise approach was used whereby
covariates associated with viral suppression (p#0.2) in univariable
analysis were considered for inclusion, and retained in the
multivariable model if p#0.2. Patients with missing outcome
(died, left employment due to ill health, lost to follow-up or missing
VL) were treated as failures; however patients who transferred out
of clinic or left employment for reasons other than ill-health were
excluded from the analysis. The Wald test was used to assess
associations and, where appropriate, linearity and effect modifi-
cation. Co-linearity was assessed by examining differences in
standard errors between univariable and multivariable models.
Programme (community vs. workplace) was an effect modifier
for multiple covariates (switch VL, transfers into programme on
first-line ART, switch reason, age: p-value for interaction,0.05)
therefore analyses are presented stratified by programme. Sensi-
tivity analyses were performed by restricting analyses to patients
who were ART-naive on initiating ART within the programme.
Analyses were undertaken using STATA v11 (College Station,
TX, USA).
Ethics
This study was approved by the research ethics committees of
the University of KwaZulu Natal, South Africa and the London
School of Hygiene and Tropical Medicine, UK.
Results
Of 14779 patients who commenced first-line ART, 555 adults
were prescribed second-line ART, of which 26 left the programme
before ART was dispensed. In total 417/529 adults (205
workplace and 212 community programme) had a documented
VL$400 copies/ml at switch and were eligible for inclusion in the
study (figure 1).
The characteristics of patients who switched to second-line
ART are presented in table 1. Compared to the community,
patients in the workplace were older, more likely to be male,
commenced first-line ART at a higher CD4 count and less
advanced clinical stage, were more likely to be ART-naive when
initiating first-line ART in the programme (10.8% vs. 52.1%) and
have a longer duration on first-line prior to switch. Non-adherence
on first-line ART was reported in a higher proportion of patients
in the workplace vs. community programme. In both programmes,
of the 62 patients classified as non-adherent on first-line ART,
21% of patients self-reported non-adherence and 84% had ART
modified or interrupted for non-adherence by healthcare workers.
More patients in the workplace programme were prescribed a
second-line regimen consistent with programme guidelines (90.7%
vs. 59.0% in the community programme); however 87.7% of
community patients did modify at least one of the NRTI backbone
drugs in addition to receiving a bPI.
A longer median duration of viraemia was observed amongst
patients in the workplace vs. community programme; 365 days
(IQR 173-538) vs. 218 days (IQR 115-394) in patients with viral
suppression on first-line ART. In both programmes there was a
median of 3 detectable VLs prior to switch (range: workplace 1-13,
community 1-10). At switch, compared to the community, patients
in the workplace programme had a higher median log10 VL (4.6
[IQR 4.1-5.1] vs. 4.3 [IQR 3.7-4.6]) and a lower median CD4
count (169 cells/mm3 [IQR 97–235] vs. 187 [IQR 95–270]).
Reasons for Switching
In both programmes treatment failure was the commonest
documented reason for switching regimens (workplace 82.2%
[148/180 patients with recorded reason] vs. community 83.8%
[161/192]). Non-adherence was recorded as a reason for switch in
7.8% (n = 14) of the workplace vs. 0.5% (n = 1) of the community
programme. 10.6% [19/180] of patients in the workplace vs.
16.1% [31/192] in the community had other reported reasons for
switching e.g. toxicity, although all were viraemic at the time of
switching.
The two VLs prior to switch were $1000 copies/ml in 80.6%
(336/417) of patients switched to second-line ART; in 16.1%
(n = 67) the VL at switch was$1000 copies/ml with the preceding
measurement 400-999 copies/ml or missing; and in 3.3% (n = 14)
the switch VL was 400-999 copies/ml with the preceding
measurement $400 copies/ml or missing.
Clinical outcomes on Second-Line Art
Outcomes stratified by programme are presented in Table 2.
73.7% (N = 179) of patients in the workplace and 84.4% (N = 151)
in the community programme were alive and in care (p,0.01) at
15 months, with 48.3% (N = 98) vs. 72.0% (N = 152), respectively,
having achieved viral suppression (p,0.01) by 15 months. Patients
in both programmes had a median of 5 VLs following switch, with
87.3% (workplace) and 88.7% (community) with $1 measure-
ment. Of the 250 patients who achieved viral suppression, 19.2%
had no further VL measurements within the follow-up period. Of
those with further measurements, 35.6% (26/73) of patients in the
workplace vs. 13.2% (17/129) of those in the community
experienced a subsequent episode of viral rebound to $400
copies/ml (p,0.01; median 3 measurements [range 2-8 work-
place, 2-5 community]). At 12 months (+/23 months), of the
patients who were still in care, 46.8% (59/126) of workplace and
72.0% (116/161) of community programme had a VL,400
copies/ml.
Outcomes on Second-Line Antiretroviral Therapy
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Patients in the workplace had a lower mean CD4 count increase
at 12 months of second-line ART than those in the community
programme (p,0.01). Non-adherence was reported in a higher
proportion of patients in the workplace, compared to the
community programme (17.9% [workplace] vs. 1.4% [communi-
ty]). In both programmes, of the 40 patients classified as non-
adherent on second-line ART, 19% were identified through
patient self-report and 83% through healthcare workers modifi-
cation or interruption of ART for non-adherence.
Predictors of Viral Suppression on Second-Line Art
Unadjusted and adjusted analysis of variables associated with
viral suppression in the workplace and community programme are
summarised in tables 3 and 4. In adjusted analysis of the
workplace programme, a lower log10 VL (adjusted risk ratio [aRR]
1.59 [95% CI: 1.09-2.34] for,4 vs. $5) and younger age (aRR
0.87 [95% CI: 0.79-0.95]/5 year increase) at switch were the
strongest predictors of viral suppression. In addition, our data
suggests an association between switch for non-adherence vs.
treatment failure (aRR 0.45 [95% CI: 0.17-1.16]) and lack of viral
suppression on second-line ART. While the association did not
reach statistical significance, the effect size was large. Duration of
viraemia was not associated with viral suppression on second-line
ART.
In adjusted analysis of the community programme, shorter
duration, but not magnitude of viraemia, predicted viral suppres-
sion (,12 months aRR 1.22 [95% CI: 1.03–1.44] vs. $12
months). Patients who were transferred into the programme on
ART, and those switched at a higher CD4 count were more likely
to suppress following switch. Sensitivity analyses of both
programmes, restricting to ART-naı¨ve patients, resulted in similar
models (data not presented).
Discussion
We have demonstrated, in a community ART programme
delivered by a network of private general practitioners and non-
government organisations, outcomes on second-line ART, both in
terms of remaining in programme and achieving viral suppression,
which are comparable to those reported from academic referral
clinics [25-26]. In contrast, in the workplace programme, over a
quarter of patients were no longer alive and in care by 15 months
of second-line ART and less than half achieved viral suppression.
The differences in outcomes by programme are of concern and
are surprising given that both programmes use similar switch
guidelines. We hypothesise that variations in healthcare workers’
switching practices, together with both individual and programme
factors, may explain these outcomes.
Figure 1. Study Flow diagram. Selection of adults for analysis, from a cohort of patients initiating first-line, NNRTI-based, ART between the 1st
January 2003 and 31st December 2008.
doi:10.1371/journal.pone.0036997.g001
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Although guidelines were similar for both programmes,
differences in switching practices were evident; patients in the
workplace were switched at a more advanced stage of immune-
suppression with a higher log10 VL, lower CD4 count and longer
duration of viraemia. This was not explained by baseline
characteristics at initiation of first-line ART; patients in the
community initiated ART at a more advanced stage of HIV than
in the workplace programme. Although prolonged viraemia in the
presence of drug pressure is associated with NRTI cross-resistance
[22-24], we do not believe that resistance is an adequate
explanation for the different virological outcomes observed
between programmes. Firstly, in settings without prior exposure
to boosted PIs, given the potency of these drugs, high rates of early
viral suppression are expected even in patients with extensive
thymidine analogue mutations [26,31-34]. Secondly, although the
duration of viraemia was shorter in the community programme,
over half of the patients were viraemic for more than 12 months
and are thus likely to also have resistance.
We hypothesise that differences in healthcare workers’ imple-
mentation of switch guidelines, and the extent to which non-
adherence is excluded prior to switching regimens, will influence
early virological outcomes on second-line ART. Current guide-
lines give little indication of how best to manage patients who are
believed to be non-adherent and who continue to experience
virological failure despite intensified adherence interventions.
Perceived non-adherence has been shown to influence healthcare
workers decisions regarding ART prescribing [35].
In the community programme a longer duration of viraemia
and lower CD4 count at switch predicted failure to achieve viral
suppression on second-line ART. A longer duration of viraemia
may be acting as a marker of non-adherence on first-line ART
(albeit that drug resistance mutations could be accumulating) with
Table 1. Baseline characteristics of patients receiving second-line ART, according to programme.
Workplace Community
N=205 (N, %) N=212 (N, %)
Age, years (median, IQR) 43 (37-49) 36 (31-42)
Sex, male 188 (91.7) 82 (38.7)
Start of first-line ART
WHO clinical stage III or IV, N=152/190 108 (71.0) 164 (86.3)
CD4 at start of first-line, cells/mm3 (median, IQR), N= 195/193 166 (91-221) 122 (43-195)
Transfers into programme on ART, N=185/192 20 (10.8) 100 (52.1)
On first-line ART
Duration on first-line pre-switch, days (median, IQR) 695 (447-1019) 517 (310-754)
Reported non-adherence 54 (26.3) 8 (3.8)
Viral suppression, 400 copies/ml, N= 190/151 130 (68.4) 108 (71.5)
At switch to second-line ART
Documented reason for switch, N=180/192
Treatment failure 147 (81.7) 160 (83.3)
Non-adherence 14 (7.8) 1 (0.5)
Other e.g. toxicity, pregnancy 19 (10.6) 31 (16.1)
Year of switch
#2005 43 (21.0) 11 (5.2)
2006-2007 57 (27.8) 84 (39.6)
2008 105 (51.2) 117 (55.2)
Number of new NRTIs in switch regimen
None 14 (6.8) 26 (12.3)
1 7 (3.4) 46 (21.7)
$2 184 (89.8) 140 (66.0)
Duration of viraemia at switch1, N= 205/207 82 (40.0) 95 (45.9)
,12 months
$12 months 123 (60.0) 112 (54.1)
Duration of viraemia between viral suppression and switch1a, days (median, IQR), N = 129/108 365 (173-538) 218 (115-394)
Duration of viraemia in ART-naı¨ve patients without viral suppression1b, days (median, IQR), N = 60/43 538 (330-766) 368 (114-544)
VL(log10) at switch (median, IQR) 4.6 (4.1-5.1) 4.3 (3.7-4.6)
CD4 at switch, cells/mm3 (median, IQR) 169 (97-235) 187 (95-270)
1Duration of viraemia was defined as (a) Patients with viral suppression on first-line ART: date of first viral load .400 copies/ml following viral suppression to date of
switch, N = 237 (57.5%)1a; (b) ART-naive patients with no viral suppression on first-line ART: date of commencing first-line ART to date of switch, N = 103 (25.0%)1b; (c)
Patients with ART-experienced pre-programme who did not achieve viral suppression on first-line ART: assumed to be $12months, N = 72 (17.4%). Abbreviations: IQR,
inter-quartile range; VL, viral load; NRTI, nucleoside reverse transcriptase inhibitor.
doi:10.1371/journal.pone.0036997.t001
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these patients requiring a longer period to address adherence
issues before the regimen is switched. However, patients consid-
ered adherent are switched quickly; this is consistent with these
individuals being more likely to achieve viral suppression.
In the workplace programme, switch VL,10000 was one of the
strongest predictors of viral suppression. While patients switched at
higher VLs may take longer to suppress, the great majority should
have achieved viral suppression by 15 months. An alternative
explanation is that a high VL reflects non-adherence [12,36].
Undisclosed non-adherence can result in healthcare worker
misclassification of the aetiology of viraemia. Healthcare worker
documented reason for switch will therefore only partially adjust
for non-adherence. In the workplace cohort 14 patients had their
NNRTI-regimen stopped for non-adherence and were switched to
second-line ART; in multivariable analysis there is a suggestion
that these patients were less likely to achieve viral suppression than
those switched for treatment failure alone. This finding is
consistent with results from other studies which report low rates
of viral suppression amongst patients switched to second-line ART
in the presence of wild-type virus [26,37-39].
Not only were patients in the workplace programme less likely
to achieve viral suppression on second-line ART, they were also
more likely to be lost to the programme and to experience viral
rebound following initial suppression. On univariable analysis of
data from the workplace programme non-adherence on second-
line ART was associated with failure to achieve viral suppression.
In the community programme the analysis was underpowered to
assess an association due to low levels of reported non-adherence.
While it is possible that failure to achieve viral suppression and
viral rebound is due to emergence of early PI resistance we feel this
is unlikely; other studies in resource-limited settings indicate that
early second-line failure is more likely to be due to non-adherence,
with PI mutations rarely seen and low PI concentrations reported
[40-42]. We believe that these early viral rebounds are secondary
to failure to sustain improved adherence behaviour which resulted
from adherence interventions implemented at the time of switch.
This could be due to contextual factors influencing patients’
adherence behaviour or failure of the health-care system to
adequately support patients at high risk of non-adherence.
Although predictors of viral suppression differed between
programmes, overall the findings are consistent with other studies;
duration and magnitude of viraemia [37,43], CD4 count at switch
[38,43], recent calendar year [44], older age [38], adherence
[25,31,37-38] and prior-ART [25] have all been shown to be
associated with second-line virological outcomes.
Other studies in this setting have also highlighted differences in
switching rates and first- and second-line outcomes by site [40,45-
49]; Pujades-Rodriguez et al. report differences in switching rates
between urban and rural sites, while others have found clinic type
to be associated with second-line virological failure [40,45]. The
underlying reasons are multi-factorial with patient, health-system
and community factors contributing [47-51].
The observed differences in programme outcomes may in part
be due to the different patient populations, both in terms of
individuals and the community, and the healthcare systems. The
workplace population was older, predominantly male, comprised
largely of migrants living in close proximity to their site of work,
with access to only one major healthcare provider. In contrast
patients accessing the community programme were younger,
mostly female, and while potentially migrants, had a choice of
healthcare provider.
Higher levels of non-adherence were reported amongst patients
on first- and second-line ART in the workplace, compared to the
community programme. While differences in non-adherence
between programmes may be due to differences in reporting,
studies conducted in this workplace setting have demonstrated
multiple barriers to maintaining adherence including lack of social
support, uncertainty about ART’s health benefits, belief in
traditional medicine and patient-provider language barriers
[48,52]. While not unique to this setting [53], these barriers may
be more prevalent amongst patients in a workplace as compared to
a community setting. Indeed higher levels of non-adherence have
been reported amongst patients enrolled in one of the workplace
clinics vs. a government public clinic [48]. Patients within the
Table 2. Outcomes at 15 months of second-line ART.
Workplace Community
N=205 (N, %) N=212 (N, %) pa
Clinical outcomes at 15 months
Alive and in care 151 (73.7) 179 (84.4) ,0.01
Diedb 12 (5.8) 12 (5.7) -
Lost to follow-up 29 (14.0) 15 (7.1) -
Transfer out - 5 (2.4) -
Other e.g. left employment 13 (6.3) 1 (0.5) -
Non-adherence reported on second-line ART 37 (17.9) 3 (1.4) ,0.01
Change in CD4 count from switch to 12m following switch, range 9-15m
(mean, 95% CI), N= 127/162
+68 (40-95) +127 (101-154) ,0.01
VL,400 within 15m of regimen start, range 2wks-15m, c N=203/211 98 (48.3) 152 (72.0) ,0.01
Viral rebound ($400) following initial viral suppression, d N= 73/129 26 (35.6) 17 (13.2) ,0.01
aChi2 was used for comparison of proportions; paired t-test was used for comparison of mean CD4 count increase;
bcause of death was available for 19/24 patients: 12 "natural causes" not further specified, 3 pneumonia, 1 tuberculosis, 1 cryptococcal meningitis, 1 gastroenteritis, 1
cerebro-vascular accident;
cPatients with missing outcome who transferred out of programme or left employment for reasons other than ill-health were excluded from the analysis (N = 2
workplace, N = 1 community). All other patients with missing outcome were treated as failures (N = 11 workplace, N = 12 community);
dPatients with $1 VL measurement following initial viral suppression (VL,400) on second-line ART.
doi:10.1371/journal.pone.0036997.t002
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workplace were older than those in the community programme
and within the workplace programme older patients were less
likely to achieve viral suppression. In many studies older age is
associated with better adherence and superior outcomes [54-59],
however this association may not be generalisable to the workplace
setting where older age is a perceived barrier to adherence [52]. In
resource-limited settings male gender has been associated with
later initiation of ART [60], defaulting [59,61-62], non-adherence
[63-64] and mortality [64-68]. The association between gender
and viral suppression varies; some studies report an association
between female gender and first-line viral suppression [69-70]
others between male gender and second-line viral suppression
[71], These studies are from different settings, from urban
townships to rural programmes; while biological characteristics
may contribute, the association with gender is likely to be
influenced by societal determinants specific to each setting. Within
the community programme we did not find any association
between gender and second-line virological suppression, and we
Table 3. Predictors of early viral suppression (viral load,400 copies/ml) on second-line ART in the workplace programme.
Viral suppression Univariable, N=203 Multivariable, N=178
N/at risk (%) RR (95% CI) pa aRR (95% CI) pa
Transfers into programme on ART, N = 184
Yes 7/20 (35.0) 0.69 (0.37-1.28)
No 83/164 (50.6) 1 0.24
Viral suppression, first-line ART, N = 189
Yes 66/130 (50.8) 1 0.53
No 27/59 (45.8) 0.90 (0.65-1.25)
Reported non-adherence, first-line ART
Yes 23/54 (42.6) 0.85 (0.60-1.20)
No 75/149 (50.3) 1 0.35
Reason for switch, N = 178
Treatment failure 76/145 (52.4) 1 1
Other 8/19 (42.1) 0.80 (0.46-1.39) 0.44 0.81 (0.49-1.34) 0.41
Non-adherence 3/14 (21.4) 0.41 (0.15-1.13) 0.08 0.45 (0.17-1.16) 0.1
Year of switch
#2007 55/100 (55.0) 1 0.06 1 0.12
2008 43/103 (41.8) 0.76 (0.57-1.01) 0.79 (0.59-1.07)
Duration of viraemia
,12 months 42/82 (51.2) 1.11 (0.83-1.47)
$12 months 56/121 (46.3) 1 0.49
VL(log10) at switch
$5 22/58 (37.9) 1 ,0.01 1 ,0.01
4-4.99 45/103 (43.7) 1.15 (0.77-1.71) 0.87 (0.58-1.33)
,4 31/42 (73.8) 1.95 (1.34-2.83) 1.59 (1.09-2.34)
CD4 at switch
,100 22/54 (40.7) 1 0.17b
100-199 36/74 (48.7) 1.19 (0.80-1.78)
$200 40/75 (53.3) 1.31 (0.89-1.93)
New NRTIs in switch regimen
#1 11/21 (52.4) 1.10 (0.71-1.69)
$2 87/182 (47.8) 1 0.68
Age at switch, per 5 years increase 98/203 (48.3) 0.86 (0.79-0.94) 0.01b 0.87 (0.79-0.95) ,0.01b
Gender
Male 87/186 (46.8) 1 0.10
Female 11/17 (64.7) 1.38 (0.94-2.03)
Reported non-adherence, second-line ARTc
Yes 12/36 (33.3) 0.47 (0.22-1.00)
No 86/167 (51.5) 1 0.05
aWald test; b test for linear trend with no evidence of departure from linearity (CD4, p = 0.84; Age, p = 0.47); c not included in the multivariable model as considered to be
on the causal pathway between exposures at time of switch and viral suppression on second-line ART.
doi:10.1371/journal.pone.0036997.t003
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were unable to assess the role of gender within the workplace as
the majority of patients were male. Finally approximately half of
the patients on second-line ART in the community programme
were transfers into care, in some cases these were patients who self-
funded first-line ART but could not afford more expensive second-
line regimens (personal communication, S Charalambous). This
was the strongest predictor of viral suppression in the community
cohort. We believe patients who transfer between healthcare
providers are likely to be highly motivated individuals [25,48]. Fox
et al. report similar findings; patients switched after only one VL,
who were considered to be transfers into care on ART, were more
likely to achieve viral suppression on second-line ART [25].
Table 4. Predictors of early viral suppression (viral load,400 copies/ml) on second-line ART in the community programme.
Viral suppression Univariable, N=211 Multivariable, N=191
N/at risk (%) RR (95% CI) pa aRR (95% CI) pa
Transfers into programme on ART, N = 191
Yes 82/100 (82.0) 1.33 (1.10-1.61) 1.33 (1.11-1.61)
No 56/91 (61.5) 1 ,0.01 1 ,0.01
Virological suppression, first-line ART, N = 150
Yes 75/108 (69.4) 1 0.56
No 27/42 (64.3) 0.93 (0.71-1.20)
Reported non-adherence, first-line ART
Yes 5/8 (62.5) 0.86 (0.50-1.49)
No 147/203 (72.4) 1 0.60
Reason for switch,b N= 190
Treatment failure 114/159 (71.7) 1 0.77
Other 23/31 (74.2) 1.03 (0.82-1.30)
Year of switch
#2007 74/95 (77.9) 1 0.08
2008 78/116 (67.2) 0.86 (0.73-1.02)
Duration of viraemia, N = 206
,12 months 72/94 (76.6) 1.11 (0.94-1.32) 1.22 (1.03-1.44)
$12 months 77/112 (68.7) 1 0.21 1 0.02
VL(log10) at switch
$5 20/29 (69.0) 1 0.59
4-4.99 80/114 (70.2) 1.02 (0.77-1.34)
,4 52/68 (76.5) 1.11 (0.84-1.46)
CD4 at switch
,100 32/54 (59.3) 1 0.01 1 0.02
100-199 56/67 (83.6) 1.41 (1.10-1.80) 1.37 (1.05-1.78)
$200 64/90 (71.1) 1.20 (0.93-1.55) 1.16 (0.88-1.52)
New NRTIs in switch regimen
#1 54/72 (75.0) 1.06 (0.90-1.26)
$2 98/139 (70.5) 1 0.48
Age at switch
,35 65/90 (72.22) 1.07 (0.83-1.38)
35-44 62/84 (73.81) 1.09 (0.84-1.41)
$45 25/37 (67.57) 1 0.80
Gender
Male 60/82 (73.2) 1 0.77
Female 92/129 (71.3) 0.97 (0.82-1.16)
Reported non-adherence, second-line ART c
Yes 1/3 (33.33) 0.19 (0.02-2.12)
No 151/208 (72.60) 1 0.16
aWald test; b only one patient switched regimens for non-adherence in the community programme. This patient has therefore been excluded as it would not be
possible to assess a potential association); c not included in the multivariable model as considered to be on the causal pathway between exposures at time of switch
and viral suppression on second-line ART.
doi:10.1371/journal.pone.0036997.t004
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This study included large patient numbers across multiple sites.
Extensive efforts were made to limit measurement bias and reduce
effects of missing data by reviewing clinic notes, verification of
switch date by cross-checking with pharmacy data, and ascertain-
ment of deaths through multiple sources (linkage to national death
register, company employment records and hospital death
register).
There are limitations to our analysis. It was based on routinely
collected programme data; clinic- and contextual level covariates
e.g. clinic staffing levels or patients’ migrant status which could
influence outcomes were not available. Due to lack of resistance
data, incomplete programme reporting of non-adherence and
inaccuracy of self-report as a measure of adherence, we were
unable to fully explore the respective roles of resistance and
adherence in early second-line virological outcomes. In addition,
as programme acted as an effect modifier for multiple covariates,
our analysis was stratified by programme. We were therefore
unable to quantify the effect of programme (workplace vs.
community) adjusted for potential confounders. Other limitations
include that, for pragmatic purposes, our definition of duration of
viraemia was a composite measure; for patients who did not
achieve viral suppression on first-line ART, duration of viraemia
was dependant on knowledge of pre-programme ART exposure
and duration in programme. While our definition was subject to
measurement error we do not believe it has resulted in bias; there
was no evidence of co-linearity between ART exposure and
duration of viraemia in the community programme multivariable
model, and using an alternative definition based on duration of
observed viraemia while in programme, similar associations were
found. Also, with no difference in frequency of virological
monitoring between programmes it is unlikely that detection bias
would explain the differences in duration of viraemia, nor indeed
virological outcomes. Finally in both second-line cohorts, the
majority of patients were cared for by four clinics and the results
may therefore be biased towards practices in these larger clinics. It
is possible that the programmatic differences we have described in
this study relate more to the individual clinics, rather than the
programmes themselves. In a larger study looking at predictors of
switching to second-line ART we found switching varied markedly
by clinic. Programme, however was not associated with switching,
nor did it account for clinic-level clustering [49]. As the majority of
clinics contributed only one to two patients to this second-line
analysis, clustering by clinic was not adjusted for.
Conclusion
The results from this study reflect the real-life dilemmas
encountered in managing virological failure and switching to
second-line ART in a resource-constrained setting. We demon-
strate that it is possible to achieve high levels of viral suppression
on second-line ART in multi-site programmes; however this is not
true of all settings with both individual- and programme-level
factors influencing outcomes. Despite similar guidelines, switching
practices differed between programmes. With no access to
resistance tests and imperfect adherence assessment tools, deciding
who is failing therapy and might benefit from switching is difficult.
The factors driving sub-optimal adherence, particularly in the
workplace programme, need addressed and strategies to support
switch decisions, such as targeted resistance tests, which may be
cost-neutral, warrant further investigation [72].
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